Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Polyphenol from grape skins and Japanese knotweed, famous for extending lifespan in yeast and mice. It has been tested in many human trials without convincing clinical benefit. Umbrella reviews rate its effects on blood sugar, cholesterol and blood pressure as trivial or very low certainty, and a meta-analysis of human brain and mood trials found the animal results are not replicated in people.
2 of 13 results reported a benefit, from 3 published studies.
3 studies, including a review of trials
Side effects: measured in 1 result. No result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultInsulin resistance, pre-diabetes, type 2 diabetes, and metabolic syndrome.
Also known as: trans-Resveratrol
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Resveratrol in blood sugar control.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysisXie K, et al. · Frontiers in psychiatry · 2026PMID 42433212 ↗02The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled TrialsNazari A, et al. · Clinical therapeutics · 2024PMID 38016844 ↗03Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-AnalysisShabil M, et al. · Medicina (Kaunas, Lithuania) · 2023PMID 36837450 ↗04Effect of saffron and fenugreek on lowering blood glucose: A systematic review with meta-analysisCorreia AGDS, et al. · Phytotherapy research : PTR · 2023PMID 36992660 ↗Be the first to share what you noticed with Resveratrol for blood sugar control. Why counts start empty.
Outcomes reported as percentage changes for Resveratrol. Other units sit in the table above.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 42268476 2026 | Systematic review | - | - | fasting blood sugar | reported qualitatively | No benefit |
| PMID 42268476 2026 | Systematic review | - | - | glycosylated hemoglobin A1c (HbA1c) | reported qualitatively | No benefit |
| PMID 42268476 2026 | Systematic review | - | - | high-density lipoprotein-cholesterol (HDL-C) | reported qualitatively | No benefit |
| PMID 42268476 2026 | Systematic review | - | - | homeostatic model assessment for insulin resistance (HOMA-IR) | reported qualitatively | No benefit |
| PMID 42268476 2026 | Systematic review | - | - | insulin | reported qualitatively | Unclear |
| PMID 42268476 2026 | Systematic review | - | - | low-density lipoprotein-cholesterol (LDL-C) | reported qualitatively | Benefit |
| PMID 42268476 2026 | Systematic review | - | - | total cholesterol (TC) | reported qualitatively | No benefit |
| PMID 42268476 2026 | Systematic review | - | - | triglyceride (TG) | reported qualitatively | No benefit |
| PMID 34320173 2021 | Meta-analysis | - | - | Cardiometabolic risk factors in type 2 diabetes (effects trivial or very low-to-low certainty) | reported qualitatively | Unclear |
| PMID 34320173 2021 | Meta-analysis | - | short term (<12 wk) | glycated hemoglobin (HbA1c), short-term trials | -1.05% (95% CI: -2.09%, -0.02%; n = 6) | Benefit |
| PMID 31978258 2020 | Meta-analysis | 50 | four weeks to five weeks | Adverse events | reported qualitatively | No benefit |
| PMID 31978258 2020 | Meta-analysis | 31 | four weeks to five weeks | Fasting blood glucose levels | 2 mg/dL (P = 0.29) | No benefit |
| PMID 31978258 2020 | Meta-analysis | 31 | four weeks to five weeks | HbA1c levels | 0.1% (P = 0.09) | No benefit |
| PMID 31978258 2020 | Meta-analysis | 36 | four weeks to five weeks | Insulin resistance | -0.35 (P = 0.27) | No benefit |